Authors
Loading...
Laboratory findings demonstrate targeting UGT2B17 reduces tumor growth in therapy-resistant prostate cancer models, suggesting it as a therapeutic target.
Kung et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: